Skip to main content

Research Repository

Advanced Search

Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease

Ezeofor, V‘S; Bray, N; Bryning, L; Hashmi, F; Hoel, H; Parker, DJ; Tudor Edwards, R

Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease Thumbnail


Authors

V‘S Ezeofor

N Bray

L Bryning

F Hashmi

H Hoel

R Tudor Edwards



Contributors

R Serra
Editor

Abstract

Background: Critical limb ischaemia is a severe stage of lower limb peripheral artery disease which can lead to tissue loss, gangrene, amputation and death. FlowOx™ therapy is a novel negative-pressure chamber system intended for home use to increase blood flow, reduce pain and improve wound healing for patients with peripheral artery disease and critical limb ischaemia. Methods: A Markov model was constructed to assess the relative cost-effectiveness of FlowOx™ therapy compared to standard care in lower limb peripheral artery disease patients with intermittent claudication or critical limb ischaemia. The model used data from two European trials of FlowOx™ therapy and published evidence on disease progression. From an NHS analysis perspective, various FlowOx™ therapy scenarios were modelled by adjusting the dose of FlowOx™ therapy and the amount of other care received alongside FlowOx™ therapy, in comparison to standard care. Results: In the base case analysis, consisting of FlowOx™ therapy plus nominal care, the cost estimates were £12,704 for a single dose of FlowOx™ therapy per annum as compared with £15,523 for standard care. FlowOx™ therapy patients gained 0.27 additional quality adjusted life years compared to standard care patients. This equated to a dominant incremental cost-effectiveness ratio per QALY gained. At the NICE threshold WTP of £20,000 and £30,000 per QALY gained, FlowOx™ therapy in addition to standard care had a 0.80 and 1.00 probability of being cost-effectiveness respectively. Conclusions: FlowOx™ therapy delivered as a single annual dose may be a cost-effective treatment for peripheral artery disease. FlowOx™ therapy improved health outcomes and reduced treatment costs in this modelled cohort. The effectiveness and cost-effectiveness of FlowOx™ therapy is susceptible to disease severity, adherence, dose and treatment cost. Research assessing the impact of FlowOx™ therapy on NHS resource use is needed in order to provide a definitive economic evaluation.

Citation

Ezeofor, V., Bray, N., Bryning, L., Hashmi, F., Hoel, H., Parker, D., & Tudor Edwards, R. (2021). Economic model to examine the cost-effectiveness of FlowOx home therapy compared to standard care in patients with peripheral artery disease. PLoS ONE, 16(1), e0244851. https://doi.org/10.1371/journal.pone.0244851

Journal Article Type Article
Acceptance Date Dec 17, 2020
Online Publication Date Jan 14, 2021
Publication Date Jan 14, 2021
Deposit Date Jan 15, 2021
Publicly Available Date Jan 15, 2021
Journal PLOS ONE
Publisher Public Library of Science
Volume 16
Issue 1
Pages e0244851
DOI https://doi.org/10.1371/journal.pone.0244851
Publisher URL https://doi.org/10.1371/journal.pone.0244851
Related Public URLs https://journals.plos.org/plosone/
Additional Information Additional Information : ** From PLOS via Jisc Publications Router ** Licence for this article: http://creativecommons.org/licenses/by/4.0/ **Journal IDs: eissn 1932-6203 **Article IDs: publisher-id: pone-d-20-16557 **History: published_online 14-01-2021; collection 2021; accepted 17-12-2020; submitted 01-06-2020
Grant Number: 737964
Grant Number: 285758

Files





Downloadable Citations